Oracle has introduced Oracle Health Sciences InForm Medication Adherence Insights Cloud Service. This solution not only enables sponsors to automatically capture precise and timely data about medication adherence, it also can help accelerate insight about drug efficacy and safety and speed clinical trials, which can, in turn, increase trial success rates.
The service is the first clinical trial data capture and management solution to automatically integrate adherence data from the Proteus Digital Health feedback system directly into an electronic data capture system. The platform helps researchers more accurately and efficiently track and manage the use of medication during clinical trials—a historically laborious and error-ridden process. The new solution also automates data collection and captures accurate medication ingestion information.
By providing direct and rapid validation of the quantity of medication a patient ingests and the time of ingestion, Oracle’s new service can help health sciences organizations lower the risk of clinical trial failures by identifying medication adherence issues early, improving dosage decisions and enhancing drug safety.
The solution also helps accelerate trials and reduce costs by eliminating imprecise, time-consuming and expensive manual processes for collecting adherence data, such as pill counts and patient questionnaires.
This solution resulted from Oracle’s strategic relationship with Proteus Digital Health. It combines Oracle’s clinical data capture and management system, Oracle Health Sciences InForm, with the Proteus Digital Health feedback system to create a product that helps pharmaceutical developers accelerate time to market while reducing costs and improving safety.
“The medication adherence option uniquely addresses the most critical information in a clinical trial: ‘Did the patients use their medicine properly?’” said Markus Christen, head of global development, Proteus Digital Health. “Combining this powerful new data with the technology, analysis, and capabilities of Oracle Health Sciences creates a game-changing opportunity for drug development.”
